Fewer PSA Tests May Benefit Older, Low-Risk Prostate Cancer Survivors, Study Says

Fewer PSA Tests May Benefit Older, Low-Risk Prostate Cancer Survivors, Study Says
A new study suggests that older patients who survived prostate cancer with a low risk of recurrence could benefit from fewer prostate cancer antigen (PSA) tests, as they are more likely to experience the harmful effects of PSA monitoring that could outweigh the advantages. The study, “Individualizing PSA Monitoring Among Older Prostate Cancer Survivors,” was published in the Journal of General Internal Medicine. In the follow-up to prostatectomy or radiation therapy to cure prostate cancer, men are monitored for disease recurrence with blood tests that measure PSA levels. Recurrence is generally considered at PSA levels equal to or higher than 0.2 ng/mL after a radical prostatectomy, or an increase over baseline by 2.0 ng/mL when radiation therapy was used. Although PSA monitoring might be beneficial for early detection of disease relapses and warrant early interventions, in some older patients the dangers of PS
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *